MHUA vs XTLB vs INVA vs CODA

For growth investors, Coda Octopus Group, Inc.

(CODA) is the stronger pick with 30. 7% revenue growth year-over-year, versus -0. 2% for Meihua International Medical Technologies Co. , Ltd. (MHUA). Meihua International Medical Technologies Co. , Ltd. (MHUA) offers the better valuation at 0. 2x trailing P/E, making it the more compelling value choice. Analysts rate Innoviva, Inc. (INVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Meihua International Medical Technologies Co.

, Ltd. (MHUA) is the cheapest at 0. 2x versus Coda Octopus Group, Inc. at 32. 2x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 1. 15x versus Coda Octopus Group, Inc. 's 5. 24x — a reasonable growth-adjusted valuation.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -99. 4% for Meihua International Medical Technologies Co. , Ltd. (MHUA). Over 10 years, the gap is even starker: CODA returned +844. 4% versus MHUA's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Meihua International Medical Technologies Co. , Ltd. 's 2. 86β — meaning MHUA is approximately 2171% more volatile than INVA relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 23% for Innoviva, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Coda Octopus Group, Inc.

(CODA) is pulling ahead at 30. 7% versus -0. 2% for Meihua International Medical Technologies Co. , Ltd. (MHUA). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -18. 4% for Meihua International Medical Technologies Co. , Ltd.. Over a 3-year CAGR, INVA leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 1. 15x versus Coda Octopus Group, Inc. 's 5. 24x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11. 9x forward P/E versus 22. 5x for Coda Octopus Group, Inc. — 10. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 65. 2% to $37. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Meihua International Medical Technologies Co. , Ltd. (MHUA) carries a higher beta of 2. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, MHUA: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MHUA (Healthcare) and XTLB (Healthcare) and INVA (Healthcare) and CODA (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MHUA is a small-cap deep-value stock; XTLB is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; CODA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.